Development and psychometric properties of the HPV Impact Profile (HIP) to assess the psychosocial burden of HPV

Current Medical Research and Opinion

Volumn 25, Issue 11, 2009, Pages 2609-2619

  Mast, T Christopher ^a   Zhu, Xingshu ^a   Demuro Mercon, Carla ^a,b   Cummings, Holly W ^a,c   Sings, Heather L ^c   Ferris, Daron G ^d  

^a MERCK RESEARCH LABORATORIES   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Human papillomavirus; Instrument development; Psychosocial; Quality of life; Questionnaire

Indexed keywords

ADULT; ARTICLE; CONDYLOMA ACUMINATUM; CONSTRUCT VALIDITY; DISCRIMINANT VALIDITY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS IMPACT PROFILE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PILOT STUDY; PSYCHOLOGICAL ASPECT; PSYCHOMETRY; QUESTIONNAIRE; RATING SCALE; RELIABILITY; SOCIAL ASPECT; VAGINA CANCER; VIRUS INFECTION; WART VIRUS;

ADOLESCENT; ADULT; ALPHAPAPILLOMAVIRUS; COMORBIDITY; COST OF ILLNESS; FEMALE; HUMANS; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PAPILLOMAVIRUS INFECTIONS; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; YOUNG ADULT;

EID: 72449167279     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903238786     Document Type: Article

References (37)

1. Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No 5 Version 2 0 IARC Press Lyon, France, 2002. Available at: http://www-dep.iarc.fr/globocan/database.htm [Last accessed 15 October 2008]
2. Sirovich BE, Welch HG. The frequency of Pap smear screening in the United States. J Gen Intern Med 2004;19:243-250 (Pubitemid 38388934)
3. Muñoz N, Castellsague X, de Gonzalez AB, et al. HPV in the etiology of human cancer. Vaccine 2006;24:S1-10
4. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006;24:S11-25
5. Lacey CJ. Therapy for genital human papillomavirus-related disease. J Clin Virol 2005;32:S82-90
6. Franco EL, Monsonego J. Epidemiology of cervical human papillomavirus infection. In: Franco EL, ed. New Developments in Cervical Screening and Prevention. Oxford, UK: Blackwell Science, 1997:14-22
7. Tortolero-Luna G. Epidemiology of genital human papillomavirus. Hematol Oncol Clin North Am 1999;13:245-257
8. Persson G, Dahlf LG, Krantz I. Physical and psychological effects of anogenital warts on female patients. Sex Transm Dis 1993;20:10-13 (Pubitemid 23082231)
9. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006;24:S35-41
10. GlaxoSmithKline Biologicals. CERVARIX® product information. GSK Australia, 2008. Available at: http://www.gsk.com.au/resources.ashx/ vaccineproductschilddataproinfo/94/FileName/7A14FBAEA16635A2DD7A68ED78E8FDDC/ PI-Cervarix.pdf. [Last accessed 15 October 2008]
11. Fleurence RL, Dixon JM, Milanova TF, et al. Review of the economic and quality-of-life burden of cervical human papillomavirus disease. Am J Obstet Gynecol 2007;196:206-212
12. Rogstad KE. The psychological impact of abnormal cytology and colposcopy. BJOG 2002;109:364-368
13. Maggino T, Casadei D, Panontin E, et al. Impact of an HPV diagnosis on the quality of life in young women. Gynecol Oncol 2007;107:S175-9 (Pubitemid 47487475)
14. Kahn JA, Chiou V, Allen JD, et al. Beliefs about Papanicolaou smears and compliance with Papanicolaou smear follow-up in adolescents. Arch Pediatr Adolesc Med 1999;153:1046-1054 (Pubitemid 29473460)
15. Cullen J, Schwartz MD, Lawrence WF, et al. Short-term impact of cancer prevention and screening activities on quality of life. J Clin Oncol 2004;22:943-952 (Pubitemid 41103607)
16. Gray NM, Sharp L, Cotton SC, et al. Psychological effects of a low-grade abnormal cervical smear test result: anxiety and associated factors. Br J Cancer 2006;94:1253-1262
17. French DP, Maissi E, Marteau TM. Psychological costs of inadequate cervical smear test results. Br J Cancer 2004;91:1887-1892 (Pubitemid 40065516)
18. Doherty IE, Richardson PH, Wolfe CD, et al. The assessment of the psychological effects of an abnormal cervical smear result and subsequent medical procedures. In Baum A, et al., eds. Cambridge Handbook of Psychology, Health and Medicine, 12th edn. Cambridge, UK: Cambridge University Press, 1991:319-324
19. Wardle J, Pernet A, Stephens D. Psychological consequences of positive results in cervical cancer screening. Psychol Health 1995;10:185-194
20. Bennetts A, Irwig L, Oldenburg B, et al. Peaps-Q - a questionnaire to measure the psychosocial effects of having an abnormal pap smear. J Clin Epidemiol 1995;48:1235-1243
21. Shinn E, Basen-Engquist K, Le T, et al. Distress after an abnormal Pap smear result: scale development and psychometric validation. Prev Med 2004;39:404-412 (Pubitemid 38834031)
22. Gray NM, Sharp L, Cotton SC, et al. Developing a questionnaire to measure the psychosocial impact of an abnormal cervical smear result and its subsequent management: the TOMBOLA (trial of management of borderline and other low-grade abnormal smears) trail. Qual Life Res 2005;14:1553-1562 (Pubitemid 40848236)
23. Woodhall S, Ramsey T, Cai C, et al. Estimation of the impact of genital warts on health-related quality of life. Sex Transm Infect 2008;84:161-166 (Pubitemid 351871484)
24. Vilata JJ, Varela JA, Olmos L, et al. Validation and clinical use of the CECA, a disease-specific quality of life questionnaire for patients with anogenital condylomata acuminata. Acta Derm Venereol 2008;88:257-262 (Pubitemid 351743869)
25. Badia X, Colombo JA, Lara N, et al. Combination of qualitative and quantitative methods for developing a new health related quality of life measure for patients with anogenital warts. Health Qual Life Outcomes 2005;3:24 (Pubitemid 41522164)
26. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol 1996;11:89-95
27. Sheehan KH, Sheehan DV. Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol 2008;23:70-83
28. Hobart JC, Riazi A, Lamping DL, et al. Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome. Health Technol Assess 2004;8:1-48 (Pubitemid 38418039)
29. Wu AW, Fink NE, Cagney KA, et al. Developing a health-related quality-of-life measure for end-stage renal disease: the CHOICE health experience questionnaire. Am J Kidney Dis 2001;37:11-21
30. Holmes W, Bix B, Shea J. SF-20 score and item distributions in a human immunodeficiency virus-seropositive sample. Med Care 1996;34:562-569 (Pubitemid 126433256)
31. Leplege A, Rude N, Ecosse E, et al. Measuring quality of life from the point of view of HIV-positive subjects: the HIV-QL31. Qual Life Res 1997;6:585-594 (Pubitemid 27431712)
32. Ware Jr JE, Gandek B. Methods for testing data quality, scaling assumptions, and reliability: the IQOLA project approach, international quality of life assessment. J Clin Epidemiol 1998;51:945-952
33. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951;16:2917
34. Snaith RP. The hospital anxiety and depression scale. Health Qual Life Outcomes 2003;1:29
35. Bjelland I, Dahl AA, Haug TT, et al. The validity of the hospital anxiety and depression scale - an updated literature review. J Psychosom Res 2002;52:69-77 (Pubitemid 34192886)
36. Pirotta M, Stein A, Conway EL, et al. The psychosocial burden of HPV-related disease and screening interventions. Sex Transm Infect 2009; In press.
37. Pitts M, Clarke T. Human papillomavirus infections and risks of cervical cancer: what do women know? Health Educ Res 2002;17:706-714